|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2018加拿大心境障碍与焦虑障碍治疗协作组/国际双相障碍学会指南:双相障碍的管理显示文摘加拿大心境障碍与焦虑障碍治疗协作组(Canadian Network for Mood and Anxiety Treatments,CANMAT)曾于2005年发布了第1版双相障碍管理指南,并分别于2007、2009和2013年对该指南进行了更新,其中最近的2次更新是与国际双相障碍学会(International Society for Bipolar Disorders,ISBD)合作完成。2018版CANMAT/ISBD双相障碍治疗指南(以下简称指南)反映了自2005年首版指南发表以来本领域取得的重大进展,包括疾病诊断与疾病管理的更新以及药物治疗与心理治疗的近期研究进展。这些前沿进展中综合考虑了循证证据的级别,并基于治疗疗效、临床实践经验、安全性、耐受性和药物导致的转相风险等,对一线、二线及三线治疗方案进行了简明而清晰的推荐。本指南中新增内容涵盖了双相Ⅰ型障碍(BD-Ⅰ)的躁狂发作急性期、抑郁发作急性期和双相障碍维持期的一线及二线治疗推荐等级划分。这种对治疗推荐等级的划分综合考虑了治疗方法对双相障碍不同时相的影响,将进一步帮助临床医生做出基于循证证据的治疗决策。锂盐、喹硫平、双丙戊酸盐、阿塞那平、阿立哌唑、帕利哌酮、利培酮和卡利拉嗪单药或联合使用被推荐为躁狂发作急性期的一线治疗选择。BD-Ⅰ抑郁期的一线治疗选择包括喹硫平、鲁拉西酮、锂盐、拉莫三嗪单药,鲁拉西酮联合锂盐或双丙戊酸盐或拉莫三嗪辅助治疗。尽管急性期治疗有效的药物通常应继续用于BD-Ⅰ的维持期治疗,但也存在一些特殊情况(例如抗抑郁药)。现有数据表明,锂盐、喹硫平、双丙戊酸盐、拉莫三嗪、阿塞那平和阿立哌唑单药或联合治疗应被视为维持治疗的初始或更换治疗方案时的一线选择。除了探讨BD-Ⅰ的相关问题外,本指南中还对双相Ⅱ型障碍(BD-Ⅱ)的临床管理进行了系统回顾并给予治疗推荐,同时针对特殊人群也有相关推荐,如处于各个生殖周期的女性、儿童、青少年和老年人。此外,本指南中还讨论了特定精神疾病及共病(如物质滥用、焦虑障碍和代谢性疾病)的影响。最后,本指南中概述了安全性和药物监测的相关问题。CANMAT/ISBD工作组希望本指南能够成为全球临床医生的实用工具。 | Lakshmi N Yatham Sidney H Kennedy Sagar V Parikh Ayal Sehaffer David J Bond Benicio N Frey Verinder Sharma Benjamin I Goldstein Soham Rej Serge Beaulieu Martin Alda Glenda MaeQueen Roumen V Milev Arun Ravindran Claire O'Donovan Diane Mclntosh Raymond W Lam Gustavo Vazquez Flavio Kapczinski Roger S Melntyre Jan Kozicky Shigenobu Kanba Beny Lafer Trisha Suppes Joseph R Calabrese Eduard Vieta Gin Malhi Robert M Post Michael Berk 胡晨(译) 王刚(译) | 2019 | 中华精神科杂志2019，52，1： | 25 |
| 2 | Viral hepatitis prevalence in patients with active and latent tuberculosis显示文摘AIM: To assess the prevalence of hepatitis B virus(HBV) and hepatitis C virus(HCV) infection and association with drug induced liver injury(DILI) in patients undergoing anti-tuberculosis(TB) therapy.METHODS: Four hundred and twenty nine patients with newly diagnosed TB- either active disease or latent infection- who were due to commence antiTB therapy between September 2008 and May 2011 were included. These patients were prospectively tested for serological markers of HBV, HCV and human immunodeficiency virus(HIV) infections- hepatitis B core antigen(HBc Ag), hepatitis B surface antigen(HBs Ag), hepatitis B e antigen, Ig G and Ig M antibody to HBc Ag(anti-HBc), HCV Ig G antibody and HIV antibody using a combination of enzyme-linked immunosorbent assay, Western blot assay and polymerase chain reaction techniques. Patients were reviewed at least monthly during the TB treatment initiation phase. Liver function tests were measured prior to commencement of antiTB therapy and 2-4 wk later. Liver function tests were also performed at any time the patient had significant nausea, vomiting, rash, or felt non-specifically unwell. Fisher's exact test was used to measure significance in comparisons of proportions between groups. A P value of less than 0.05 was considered statistically significant.RESULTS: Of the 429 patients, 270(62.9%) had active TB disease and 159(37.1%) had latent TB infection. 61(14.2%) patients had isolated anti-HBc positivity, 11(2.6%) were also HBs Ag positive and 7(1.6%) were HCV-antibody positive. 16/270 patients with active TB disease compared to 2/159 patients with latent TB infection had markers of chronic viral hepatitis(HBs Ag or HCV antibody positive; P = 0.023). Similarly the proportion of HBs Ag positive patients were significantly greater in the active vs latent TB infection group(10/43 vs 1/29, P = 0.04). The prevalence of chronic HBV or HCV was significantly higher than the estimated United Kingdom prevalence of 0.3% for each. We found no association between DILI and presence of serological markers of HBV or HCV. Three(5.3%) patients with serological markers of HBV or HCV infection had DILI compared to 25(9.5%) patients without; P = 0.04.CONCLUSION: Viral hepatitis screening should be considered in TB patients. DILI risk was not increased in patients with HBV/HCV. | Hesam Ahmadi Nooredinvand David W Connell Mahmoud Asgheddi Mohammed Abdullah Marie O'Donoghue Louise Campbell Melissa I Wickremasinghe Ajit Lalvani Onn Min Kon Shahid A Khan | 2015 | World Journal of Gastroenterology2015，21，29： | 7 |
| 3 | FK506对实验性卒中疗效的系统评价和Meta分析显示文摘FK506是治疗急性卒中的一种候选用药。决定一种药物是否可以用于临床试验,应当以全面的、无偏倚的动物实验数据的评估为依据,同时还应考虑到这些数据的局限性。这种评估不但应包括药物疗效,而且也应包括药效在体内的特征和局限性。本研究应用系统评价和Meta分析的方法对FK506在卒中动物模型中保护作用的证据进行评价。总共纳入了29个描述了实验步骤的研究,包括1759只动物。结果显示,FK506疗效的点估计值(结局指标的改善)是31.3%[95%CI(0.272-0.354)]。在采用氯胺酮麻醉和短暂性脑缺血的动物实验中,FK506的疗效更高,在使用大鼠,合并其他疾病的动物及仅以梗死面积为疗效指标的实验中,FK506疗效较低。已发表的实验研究质量均接近临床试验标准,但在高质量的研究中,FK506的疗效较低。FK506在实验性脑卒中的研究中,虽然显示出有明显的疗效,但是应注意由于研究质量和可能的发表偏倚等冈素的影响,FK506的疗效可能被过高估计。 | Malcolm R Macleod Tori O’Collins Laura L Horky David W Howells Geoffrey A Donnan 段建钢 | 2006 | 中国循证医学杂志2006，6，6： | 3 |
| 4 | The digital micromirror device for projection display显示文摘 | Gale Richard O | 1995 | Microelectronic Engineering1995，27，： | 1 |
| 5 | Mortality and suicide after non-fatal self-poisoning:16-year outcome study显示文摘 | David O Chritopher W | | 0，，05： | 1 |
| 6 | 显示文摘 | David W I F Jones M O | 2007 | J Am Chem Soc2007，129，： | 1 |
| 7 | A Reviewand Analysis of Current Computer-Aided Fixture DesignApproaches 显示文摘 | B O Y L E Iain R O N G Yiming B R O W N David C | 2011 | Robotics and Computer-Integrated Manufacturiiig2011，27，1： | 1 |
| 8 | Manipulating dendritic cell biology for the active immunotherapy of cancer显示文摘 | DAVID W O'NEILL SYLVIA ADAMS | 2004 | Blood2004，104，8： | 1 |
| 9 | Role of determinants of cadmium sensitivity in the tolerance of Schizosaccharomyces pombe to cisplatin显示文摘 | PEREGO P WEGHE J V DAVID W O | | 0，，01： | 1 |
| 10 | Long wave infrared polarimetric modeh theory, measurements and parameters显示文摘 | David W Steve O David B | 2006 | Journal of Optics A: Pure and Applied Optics2006，8，10： | 1 |
| 11 | Consumer self-confidence: Refinements in conceptualization and measurement 显示文摘 | BEARDEN W O DAVID M H RANDALL L R | 2001 | Journal of Consumer Research2001，28，1： | 1 |
| 12 | A new strategy for harnessing knowledge management in e-commerce显示文摘 | STEPHEN A O DAVID C Y JEFFREY W M | 2005 | Technology in Society2005，27，： | 1 |
| 13 | Current routes in polycrystalline CuInSe2 andCu(In,Ga)Se2 films显示文摘 | AZULAY D MILLO O BALBERG I SCHOCK H W IRIS V F DAVID C | 2007 | Solar Energy Materials and Solar Cells2007，91，1： | 1 |
| 14 | The effect of heat, cold, and prolonged storage on a granulosis virus of Pieris rapae显示文摘 | DAVID W A L GARDINER B O C | 1967 | J Invertebr Pathol1967，9，： | 1 |
| 15 | Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women显示文摘 | George W Peter T Beverley S Gordon G Joan P Nicole Z Vivian R David H Diane O Ann C | 2002 | Endocrine Reviews2002，23，4： | 1 |
| 16 | The 2007 WHO classification of tumours of the central nervous system显示文摘 | David L Hiroko O Otmar W | | 0，，： | 1 |
| 17 | Direct evidence for a low frequency phonon modemechanism in the negative thermal ex-pansion compound ZrW2O8显示文摘 | DAVID W I F EVANS J S O SLEIGHT A W | 1999 | Eur PhysLett1999，46，： | 1 |
| 18 | Transferable dis charge permits and economic efficiency: The Fox River显示文摘 | O'NEIL W DAVID M MOORE C | 1983 | Journal of Environmental Economics and Management1983，10，4： | 1 |
| 19 | Wide-area augmented real- ity using camera tracking and mapping in multiple regions 显示文摘 | ROBERT O C GEORG K DAVID W M | 2011 | Com- puter Vision and Image Understanding2011，115，6： | 1 |
| 20 | Structural Investigation of the Negative-Thermal-Expansion Material ZrW2O8显示文摘 | J S O Evans W I F David A W Sleight | 1999 | Acta Crystallography1999，55，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员